BeOne Medicines

Dr. Guillem Lomas talk with soccer goaltender legend @TimHow1x about how cancer touched his life, his partnership with @BeOneMedicines and his #WorldCup experiences and @fifa_world_cup_2026 predictions next on Sports Medicine

#News for #Investors and #Media: We’ve got an exciting few weeks ahead. At #ASCO26 and #EHA26, we’re mapping the future of care in B-cell malignancies while showcasing our accelerating solid tumor portfolio. Across both congresses, 60+ abstracts highlight the depth of our science and momentum in oncology. Join us at #ASCO26 and #EHA26 and explore more: ir.beonemedicines.com/news/beone-med… #BeOneInnovator

@CllSociety recently highlighted six-year follow-up data from our global Phase 3 SEQUOIA study evaluating our BTK inhibitor in patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), with or without del(17p) and/or TP53 mutations. Learn more about this important data and what it means for high-risk patients here: cllsociety.org/2026/05/zanubr… #CLL #SLL #BeOneAgainstCancer

For patients with relapsed or refractory mantle cell lymphoma, options are limited and outcomes can be challenging. That reality drives our innovation at BeOne. Our Chief Medical Officer Amit Agarwal, M.D., Ph.D., shares how our BCL2 inhibitor – the first and only in its class FDA-approved in this setting – represents an important step forward for patients who need new options. Find out more: ir.beonemedicines.com/news/beone-med… #BeOneInnovator #TeamBeOne

#News for #Investors and #Media: The U.S. FDA has granted accelerated approval for our foundational BCL2 inhibitor in relapsed/refractory mantle cell lymphoma — the first and only in R/R #MCL. Full announcement: ir.beonemedicines.com/news/beone-med… #Oncology #BeOneOnnovator

#News for #Investors and #Media: BeOne Medicines announces first quarter 2026 financial results and business updates. Read the full press release here: ir.beonemedicines.com/news/beone-med…

#News for #Investors and #Media: BeOne Medicines is pleased to announce the FDA has granted Priority Review for our PD-1 inhibitor in combination with a HER2-directed antibody and chemotherapy for the first-line treatment of HER2+ gastroesophageal adenocarcinoma. Read the full press release here: ir.beonemedicines.com/news/us-fda-gr… #Oncology #CancerResearch #GEA

Today is WM World Awareness Day. Join the IWMF for all the latest updates in research, education, and support for those affected by Waldenstrom! iwmf.com/join-the-iwmf/ We are stronger together. #Waldenstrommacroglobulinemia #strongertogether #IWMF #WMWorldAwarenessDay2026

AI is already changing how blood cancer patients navigate their care. We shared with @USATODAY how BeOne is bringing patients and advocates to the table to shape AI tools that are accurate, trustworthy, and built around real-world needs of patients. Read and learn more: usatoday.com/story/sponsor-… @MediaplanetUSA

We are reaffirming our commitment to advancing lung cancer care at #ELCC2026. Our exhibit brings BeOne’s impact to life with a dynamic 3D sphere highlighting our global presence, cutting-edge clinical research, and our momentum bringing solid tumor treatments to more patients. The sphere represents our collaborative spirit, scientific excellence, and unwavering commitment to patients around the world. #BeOneAgainstCancer #TeamBeOne

#News for #Investors and #Media: The FDA has granted our GPC3x4-1BB bispecific antibody Orphan Drug Designation in hepatocellular carcinoma (HCC). #LiverCancer #HCC #BeOneInnovator

Meet Kristian Stubbs, our General Manager, Canada at BeOne. Driven by a personal connection to cancer, he is committed to expanding access to our innovative cancer therapies to the people who need them. Swipe to learn more. #TeamBeOne

Impact is not only measured by what we achieve, but also how we show up for others. As part of our commitment to creating a positive impact, the BeOne Care Foundation supports initiatives that eliminate barriers to accessible cancer care in underserved communities. From funding critical programs to driving disease awareness, swipe to learn how we helped to make a difference in 2025 through our Access to Cancer Care grants. #BeOneAgainstCancer #PatientsFirst

Elevating the patient voice is central to BeOne’s efforts to unite the worldwide community against cancer. Today, we are sharing an article published in @GiOncNow that highlights urgent challenges raised by patients, caregivers, and clinicians at Hope for Stomach Cancer's 4th Patient Empowerment Summit. These perspectives, many offered directly by patients, provide important guidance for the GI oncology community as we work together to close gaps in gastric cancer care. Read the article here: gioncologynow.com/page/patient-p…

🌍 It’s #RareDiseaseDay 2026! 💜 Today we stand with the 300 million people living with a rare disease. Together, we’re showing our colours, raising awareness, and inspiring change by talking about what equity means to us. 👉 Read more: go.rarediseaseday.org/NEWS

This #RareDiseaseDay we’re shining a light on the 300 million people worldwide living with a rare disease. While each rare disease is unique, there are many shared challenges, including delayed or missed diagnoses, limited care options, research and data limitations, and barriers to access. At BeOne, we’re committed to improving treatment options for those affected by rare diseases like Mantle Cell Lymphoma (MCL), a type of blood cancer. Join us in raising awareness, sharing support, and standing with the rare disease community today. #BeOneAgainstCancer #MCL

#News for #Investors and #Media: BeOne Medicines announces fourth quarter and full-year 2025 financial results and business updates. Read the full press release here: ir.beonemedicines.com/news/beone-med…

In the latest Cancer Has No Borders podcast episode, our Head of Europe, Giancarlo Benelli, discusses how growth in Europe will play a critical role for our global business. Learn more about our commitment to developing more effective and inclusive trials for patients across the region here: youtu.be/expUgmLYZ2k?si… Or listen on your favorite podcast platform: Apple: podcasts.apple.com/us/podcast/epi… Spotify: open.spotify.com/episode/0aSTyq… #BeOneAgainstCancer